Developer docs
API playgroundTry for free, no card

Search company profiles

sperogenix

Full company profile

uuid002mrde

Namestring
sperogenix
Websiteurl
sperogenix.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Sperogenix is a privately held, China-based biopharmaceutical company founded in 2019 and headquartered in Chaoyang, Beijing. According to firmographic data, the company operates a platform-based business model dedicated to the research and development and commercialization of rare disease therapeutics — a therapeutic category characterized by small patient populations, complex clinical development, and post-approval regulatory exclusivity. Sperogenix has a workforce of 51-100 employees and maintains a Chinese operating geography, with a public website at sperogenix.com that, at the time of data capture, displays only a default nginx placeholder page rather than active corporate content.

From a business-model perspective, Sperogenix follows the standard specialty-pharma trajectory: a pre-commercial or early-clinical R&D operation that intends to generate future revenue through proprietary drug commercialization and, in some cases, licensing or partnership income. The available data does not document specific drug candidates, therapeutic-area focus, pipeline depth, partnerships, pricing models, customer segments, or commercialization milestones, and the company has no disclosed public ticker, parent company, or detailed ownership structure.

The absence of recorded patents, trademarks, certifications, regulatory actions, M&A activity, leadership team bios, or strategic partnerships materially constrains visibility into the company's operational specifics. The only verifiable recent strategic event is a second funding round recorded on 2025-06-06 with undisclosed amount and undisclosed investors. As a result, while Sperogenix's category positioning (rare disease drug developer in China) is clear, the underlying technology architecture, competitive position, and go-to-market mechanics cannot be substantively characterized from the supplied inputs.

Short descriptiontext

Sperogenix is a privately held Chinese biopharmaceutical company founded in 2019 and headquartered in Chaoyang, Beijing, operating a platform-based R&D and commercialization business focused on therapies for rare diseases.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChaoyang, China
HQ citystring
Chaoyang
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
rare disease drugs, pharmaceutical research, drug development, biopharmaceutical platform, rare disease therapeutics
Industry2 codes
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Disease Therapeutics
No data
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sperogenix is a platform-based biopharmaceutical company that conducts the research, development, and commercialization of therapies for rare diseases. The company integrates drug discovery and development activity with commercialization to bring rare disease treatments to market.

Differentiator
Functional benefit
Problem solved
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers9 records
TypeBroad incumbent
Description

Commercial-stage rare disease company developing therapies for rare and ultra-rare genetic diseases, providing a relevant comparator for platform economics, pipeline diversification, and commercialization strategy in rare disease.

TypeBroad incumbent
Description

Established global rare disease company specializing in treatments for serious and life-threatening rare genetic conditions; serves as the global benchmark for the rare disease commercial model that Sperogenix is attempting to replicate in China.

3Genor Biopharma
TypeRegional player
Description

China-based biopharmaceutical company focused on oncology and autoimmune diseases; comparable as a similarly-sized, China-domiciled clinical-stage biopharma facing the same regulatory and capital access dynamics.

4LianBio
TypeDirect peer
Description

China-focused clinical-stage biopharmaceutical company partnering with global innovators to bring therapies to Chinese patients, including rare and serious disease assets with a comparable cross-border licensing model.

TypeDirect peer
Description

China-based clinical-stage biopharmaceutical company focused on licensing and developing innovative therapies, with a significant emphasis on rare disease and specialty indications in the Greater China region.

TypeDirect peer
Description

China-focused rare disease company developing and commercializing therapies for rare and orphan indications, with a comparable platform-style approach and similar geographic focus on serving Chinese patients with rare conditions.

7I-Mab Biopharma
TypeRegional player
Description

China-based clinical-stage biopharmaceutical company developing innovative biologics; comparable as a similarly-sized Chinese biotech navigating capital markets and regulatory pathways in the same regional environment.

TypeBroad incumbent
Description

Global pharmaceutical major with one of the largest rare disease franchises through Genzyme, covering lysosomal storage disorders and other rare conditions; representative of the dominant incumbent rare disease commercial model.

TypeBroad incumbent
Description

Global pharmaceutical company with a substantial rare disease and plasma-derived therapies franchise following the Shire acquisition; relevant as a large incumbent with established rare disease commercial infrastructure.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

sperogenix

Rare Disease Therapeuticssperogenix.com

Sperogenix is a privately held Chinese biopharmaceutical company founded in 2019 and headquartered in Chaoyang, Beijing, operating a platform-based R&D and commercialization business focused on therapies for rare diseases.

What sperogenix does

Sperogenix is a privately held, China-based biopharmaceutical company founded in 2019 and headquartered in Chaoyang, Beijing. According to firmographic data, the company operates a platform-based business model dedicated to the research and development and commercialization of rare disease therapeutics — a therapeutic category characterized by small patient populations, complex clinical development, and post-approval regulatory exclusivity. Sperogenix has a workforce of 51-100 employees and maintains a Chinese operating geography, with a public website at sperogenix.com that, at the time of data capture, displays only a default nginx placeholder page rather than active corporate content.

From a business-model perspective, Sperogenix follows the standard specialty-pharma trajectory: a pre-commercial or early-clinical R&D operation that intends to generate future revenue through proprietary drug commercialization and, in some cases, licensing or partnership income. The available data does not document specific drug candidates, therapeutic-area focus, pipeline depth, partnerships, pricing models, customer segments, or commercialization milestones, and the company has no disclosed public ticker, parent company, or detailed ownership structure.

The absence of recorded patents, trademarks, certifications, regulatory actions, M&A activity, leadership team bios, or strategic partnerships materially constrains visibility into the company's operational specifics. The only verifiable recent strategic event is a second funding round recorded on 2025-06-06 with undisclosed amount and undisclosed investors. As a result, while Sperogenix's category positioning (rare disease drug developer in China) is clear, the underlying technology architecture, competitive position, and go-to-market mechanics cannot be substantively characterized from the supplied inputs.

sperogenix firmographics

Firmographics
Name
sperogenix
Website
https://sperogenix.com
Company type
Private
Founded year
2019
Headcount range
11–50 employees
Short description
Sperogenix is a privately held Chinese biopharmaceutical company founded in 2019 and headquartered in Chaoyang, Beijing, operating a platform-based R&D and commercialization business focused on therapies for rare diseases.
Ownership category
akta.pro rank

sperogenix industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease drugs
  • Pharmaceutical research
  • Drug development
  • Biopharmaceutical platform
  • Rare disease therapeutics

Where sperogenix is headquartered

Location

Headquarters

HQ city
Chaoyang
HQ country
China
HQ region
Asia

Markets served

sperogenix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

sperogenix product offering

Product offering

Core offering

Sperogenix is a platform-based biopharmaceutical company that conducts the research, development, and commercialization of therapies for rare diseases. The company integrates drug discovery and development activity with commercialization to bring rare disease treatments to market.

Differentiator

Problem solved

Functional benefit

Companies that use sperogenix

Customer profile

Ideal customer profiles1 record

sperogenix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

sperogenix partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights3 records

sperogenix competitors and assessment

Company assessment

Broad incumbents

  • Ultragenyx Pharmaceutical: Commercial-stage rare disease company developing therapies for rare and ultra-rare genetic diseases, providing a relevant comparator for platform economics, pipeline diversification, and commercialization strategy in rare disease.
  • BioMarin Pharmaceutical: Established global rare disease company specializing in treatments for serious and life-threatening rare genetic conditions; serves as the global benchmark for the rare disease commercial model that Sperogenix is attempting to replicate in China.
  • Sanofi (Genzyme) - Rare Disease: Global pharmaceutical major with one of the largest rare disease franchises through Genzyme, covering lysosomal storage disorders and other rare conditions; representative of the dominant incumbent rare disease commercial model.
  • Takeda Pharmaceutical (Rare Disease): Global pharmaceutical company with a substantial rare disease and plasma-derived therapies franchise following the Shire acquisition; relevant as a large incumbent with established rare disease commercial infrastructure.

Regional players

  • Genor Biopharma: China-based biopharmaceutical company focused on oncology and autoimmune diseases; comparable as a similarly-sized, China-domiciled clinical-stage biopharma facing the same regulatory and capital access dynamics.
  • I-Mab Biopharma: China-based clinical-stage biopharmaceutical company developing innovative biologics; comparable as a similarly-sized Chinese biotech navigating capital markets and regulatory pathways in the same regional environment.

Direct peers

  • LianBio: China-focused clinical-stage biopharmaceutical company partnering with global innovators to bring therapies to Chinese patients, including rare and serious disease assets with a comparable cross-border licensing model.
  • Everest Medicines: China-based clinical-stage biopharmaceutical company focused on licensing and developing innovative therapies, with a significant emphasis on rare disease and specialty indications in the Greater China region.
  • CANBridge Pharmaceuticals: China-focused rare disease company developing and commercializing therapies for rare and orphan indications, with a comparable platform-style approach and similar geographic focus on serving Chinese patients with rare conditions.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

sperogenix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

sperogenix leadership team

Management profile

Number of profiles

sperogenix funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

sperogenix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about sperogenix

What does sperogenix do?

Sperogenix is a platform-based biopharmaceutical company that conducts the research, development, and commercialization of therapies for rare diseases. The company integrates drug discovery and development activity with commercialization to bring rare disease treatments to market.

When was sperogenix founded?

sperogenix was founded in 2019. It employs 11 to 50 people.

Where is sperogenix based?

sperogenix is headquartered in Chaoyang, China, in the Asia region.

Who are sperogenix's main competitors?

Broad incumbents on record are Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, Sanofi (Genzyme) - Rare Disease and Takeda Pharmaceutical (Rare Disease). Regional players are Genor Biopharma and I-Mab Biopharma. Direct peers are LianBio, Everest Medicines and CANBridge Pharmaceuticals.

Does sperogenix have an API?

No public API is recorded for sperogenix.

What industry is sperogenix in?

sperogenix's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies, with a secondary code of HLAIAIAL, Rare Gastroenterology & Hepatology Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireSanthera Closes USD 13 Million Royalty Monetization AgreementSanthera Pharmaceuticals has closed a USD 13 million royalty monetization agreement to support the global launch of AGAMREE® (vamorolone), with Partners Group joining as the majority contributor alongside R-Bridge. The agreement covers 25% of net royalties on AGAMREE from Catalyst Pharmaceuticals in North America and Sperogenix Therapeutics in China, with capped payments and buy-back rights retained by Santhera. This financing provides growth capital for Santhera's global rollout strategy of AGAMREE, which is approved for Duchenne muscular dystrophy treatment in the U.S., EU, UK, China, and Canada.PR NewswireAbbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater ChinaSperogenix and Abbisko Therapeutics have entered into an exclusive licensing agreement for the development and commercialization of the drug ABSK021 in mainland China, Hong Kong, and Macao. Under the terms, Sperogenix will lead clinical trials and commercialization efforts for ALS and other rare neurological diseases, while Abbisko retains rights for other territories and indications. This partnership aims to accelerate the delivery of innovative therapies for ALS, a condition with limited treatment options in China.PR NewswireMinoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and MacauMinoryx Therapeutics and Sperogenix Therapeutics have entered into an exclusive license agreement granting Sperogenix exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD) in mainland China, Hong Kong, and Macau. Minoryx will receive upfront and milestone payments of up to $78 million, plus double-digit royalties on annual net sales, while leriglitazone has received Orphan Drug Designation in the U.S. and Europe and is currently in Phase 2/3 trials with data expected by end of 2020.